Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022 Pre-NDA Meeting for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma Scheduled for the Fourth Quarter of 2022 Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy Expected in the Third or Fourth … [Read more…]
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Global Genes, a leading rare disease patient advocacy organization, today announced its annual RARE Champions of Hope award winners, recognizing leaders and organizations for their inspiring work in driving innovation, advocacy and change in rare disease as part of the 2022 RARE Disease Patient Advocacy Summit in San Diego. This year, the … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir, will present a corporate overview at the UBS Biotechnology Virtual Private Company Symposium on … [Read more…]
New features round out human services offering in industry’s only comprehensive EHR platform to encompass physical, dental and behavioral health ATLANTA–(BUSINESS WIRE)–$NXGN #NextGenHealthcare–NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced the newest release of its NextGen® Behavioral Health Suite. Built upon the company’s award-winning NextGen® Enterprise electronic … [Read more…]
One out of Ten Patients Served by CareDx Signals Broad Uptake of Company’s Non-Invasive Testing Services for Heart, Kidney, and Lung Transplant Patients BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that … [Read more…]
SOUTHLAKE, Texas–(BUSINESS WIRE)–OncoNano Medicine, Inc. today announced a presentation of data from its ongoing Phase 2 study of pegsitacianine at the World Molecular Imaging Congress (WMIC), occurring September 27 – October 1, 2022. The presentation will be given during the Cancer: Innovations in Molecular Imaging session. Details of the oral presentation are as follows: Presentation … [Read more…]
LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that President and Chief Executive Officer Jon Serbousek and Chief Financial Officer Doug Rice will be presenting during the upcoming Sidoti Virtual Investor Conference on Wednesday, September 21, 2022 at 10:00 a.m. ET. The conference will … [Read more…]
Joe Jonas and STAAR Host Media Day in NYC EVO ICL Patient Education Expanded to Social Media and YouTube with Millions of Views LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided an update on activities related to … [Read more…]
– Capstan’s foundation is built on research developed by world-renowned mRNA and cell therapy scientists and clinicians at the University of Pennsylvania – Therapy development focused on cell type-specific engineering across oncology, autoimmune disease, blood disorders, and fibrosis – $165 million seed and Series A financings include significant investment from leading biopharmaceutical companies including Pfizer … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Hemophilia Market Analysis by Type (Type A, B, C,), by Treatment (Prophylaxis, On-Demand), by Therapy (Gene, Replacement, Immune Tolerance Induction (ITI) Therapy), and by Region – Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The global hemophilia market size is estimated to be USD 12.6 billion in 2021 and is expected … [Read more…]
